Premium
Quantity, quality, and functionality of peripheral blood cells derived from residual blood of different apheresis kits
Author(s) -
Knörck Arne,
Marx Stefanie,
Friedmann Kim S.,
Zöphel Sylvia,
Lieblang Lisa,
Hässig Carmen,
Müller Isabelle,
Pilch Jan,
Sester Urban,
Hoth Markus,
Eichler Hermann,
Sester Martina,
Schwarz Eva C.
Publication year - 2018
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.14616
Subject(s) - apheresis , peripheral blood mononuclear cell , whole blood , cd8 , cytotoxic t cell , flow cytometry , immunology , blood product , medicine , chemistry , andrology , immune system , in vitro , platelet , pathology , biochemistry
BACKGROUND Research with primary human white blood cell (WBC) subpopulations requires high quantity, quality, and functionality of peripheral blood mononuclear cells (PBMCs) as a source to further characterize cellular subpopulations such as T and B lymphocytes, monocytes, or natural killer cells. Apart from buffy coats derived from whole blood, residual blood from preparative hemapheresis kits are used as a source for PBMCs, but knowledge on the yield and functionality of cells from different devices is limited. STUDY DESIGN AND METHODS We evaluated quantity and quality of PBMCs isolated from apheresis kits of two apheresis devices (AMICUS, Fenwal; and Trima Accel, Terumo BCT), the latter being our standard source for many years. PBMCs derived from Trima or AMICUS were tested for yield and subtype composition by flow cytometry. Functionality was assessed by cytokine induction of CD4 + and CD8 + T cells and by degranulation. Moreover, cytotoxic activity of natural killer cells was quantified by a real‐time killing assay. RESULTS Mean numbers of isolated cells were 5.5 ± 2.4 × 10 8 for AMICUS, and 10.3 ± 6.4 × 10 8 for Trima Accel, respectively. The proportion of WBC subtypes corresponded to well‐known numbers from whole blood, with minor differences between the two apheresis systems. Likewise, minor differences in cytokine induction were found in stimulated CD4 + or CD8 + T cells. Finally, PBMCs derived from the two systems showed comparable cytotoxic activity. CONCLUSION PBMC derived from residual blood of the AMICUS and Trima Accel apheresis devices serve as an economic and easily accessible source for functional PBMCs with comparable quantity and quality to PBMCs derived from whole blood.